Erica L. Beatson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erica L. Beatson has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Adam G. Sowalsky
Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA
19 shared publications - Andres F. Leon
Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
19 shared publications - Benjamin C. Brim
National Cancer Institute, National Institutes of Health Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research Bethesda, MD, 20892
19 shared publications - Carleen Klumpp-Thomas
National Center for Advancing Translational Sciences
19 shared publications - Cindy H. Chau
Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
19 shared publications - Craig J. Thomas
National Institutes of Health
19 shared publications
Latest Publications
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S4 shows protein level changes after 24 hours of treatment with DMSO, A-1331852, S63845, or the combination of A-1331852 and S63845.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S4 shows protein level changes after 24 hours of treatment with DMSO, A-1331852, S63845, or the combination of A-1331852 and S63845.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Co-targeting Mcl-1 and Bcl-xL enhances the inhibitory effect on cell viability. The effect on cell viability of A-1331852 (targeting Bcl-xL) in combination with S63845 (targeting Mcl-1; A–C) and navitoclax (targeting Bcl-xL and Bcl-2) in combination with S63845 (D–F). Cell viability was determined following either 48-hour (22Rv1 and LNCaP-95) or 72-hour treatment (VCaP-CR) by CellTiter-Glo luminescent assay. The data provided represent the mean ± SD from three independent experiments with at least three technical replicates per experiment.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Co-targeting Mcl-1 and Bcl-xL enhances the inhibitory effect on cell viability. The effect on cell viability of A-1331852 (targeting Bcl-xL) in combination with S63845 (targeting Mcl-1; A–C) and navitoclax (targeting Bcl-xL and Bcl-2) in combination with S63845 (D–F). Cell viability was determined following either 48-hour (22Rv1 and LNCaP-95) or 72-hour treatment (VCaP-CR) by CellTiter-Glo luminescent assay. The data provided represent the mean ± SD from three independent experiments with at least three technical replicates per experiment.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Table S2 compares the IC50 values of BH3 mimetics as single agents across 2D culture and 3D spheroids.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Table S2 compares the IC50 values of BH3 mimetics as single agents across 2D culture and 3D spheroids.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S6 shows the effect of treamtent of 3D spheroids with BH3 mimetics as single agents or in combination.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S6 shows the effect of treamtent of 3D spheroids with BH3 mimetics as single agents or in combination.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Table S1 depicts the IC50 values of BH3 mimetics as single agents in 2D models.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Table S1 depicts the IC50 values of BH3 mimetics as single agents in 2D models.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S2 shows the single agent activity of BH3 mimetics across LNCaP95, VCaP-CR, and 22Rv1 cells.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S2 shows the single agent activity of BH3 mimetics across LNCaP95, VCaP-CR, and 22Rv1 cells.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Optimal dose evaluation for co-targeting Bcl-xL and Mcl-1. Dose–response heatmaps (A–C and G–I) and Bliss synergy plots (D–F and J–L) for A-1331852-based (A–F) and navitoclax-based (G–L) combinations with S63845 were obtained using the SynergyFinder+ R package. Plots were generated using data from 2D cell culture experiments in LNCaP95 (A, D, G, and J), VCaP-CR (B, E, H, and K), and 22Rv1 (C, F, I, and L). Data provided represent mean ± SD from three individual experiments.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Optimal dose evaluation for co-targeting Bcl-xL and Mcl-1. Dose–response heatmaps (A–C and G–I) and Bliss synergy plots (D–F and J–L) for A-1331852-based (A–F) and navitoclax-based (G–L) combinations with S63845 were obtained using the SynergyFinder+ R package. Plots were generated using data from 2D cell culture experiments in LNCaP95 (A, D, G, and J), VCaP-CR (B, E, H, and K), and 22Rv1 (C, F, I, and L). Data provided represent mean ± SD from three individual experiments.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S7 depicts morphological changes of the LuCaP-167CR organoids after treatment with BH3 mimetics as single agents or in combination.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S7 depicts morphological changes of the LuCaP-167CR organoids after treatment with BH3 mimetics as single agents or in combination.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S8 depicts the single agent activity of XZ739 across 2D culture.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S8 depicts the single agent activity of XZ739 across 2D culture.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often develop resistance to next-generation hormonal therapies that target the androgen receptor (AR) axis (e.g., abiraterone and enzalutamide). A splice variant of AR, AR-V7, is associated with resistance to these inhibitors as well as mCRPC progression and poor prognoses. We embarked upon a high-throughput screen to identify synergistic combinations of targeted therapies using two CRPC cell lines, LNCaP95 and VCaP-CR. Combinations targeting BCL2L1 (Bcl-xL) (A-1331852 and navitoclax) and MCL1 (S63845) synergistically decreased cell viability and induced apoptotic activity via cleavage of PARP, caspase 3, and caspase 7 across AR-V7–expressing CRPC cell lines (LNCaP95, VCaP-CR, and 22Rv1) and a patient-derived organoid model (LuCaP 167CR). We also explored the use of a Bcl-xL–specific proteolysis-targeting chimera degrader (PROTAC) to minimize platelet toxicity associated with Bcl-xL inhibitors. We showed similar synergistic efficacy with the Bcl-xL–targeting PROTAC in combination with S63845 in the three-dimensional spheroid models. Our findings support further preclinical development of Bcl-xL and Mcl-1 inhibitors for mCRPC.Significance:Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7–expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7–expressing CRPC.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often develop resistance to next-generation hormonal therapies that target the androgen receptor (AR) axis (e.g., abiraterone and enzalutamide). A splice variant of AR, AR-V7, is associated with resistance to these inhibitors as well as mCRPC progression and poor prognoses. We embarked upon a high-throughput screen to identify synergistic combinations of targeted therapies using two CRPC cell lines, LNCaP95 and VCaP-CR. Combinations targeting BCL2L1 (Bcl-xL) (A-1331852 and navitoclax) and MCL1 (S63845) synergistically decreased cell viability and induced apoptotic activity via cleavage of PARP, caspase 3, and caspase 7 across AR-V7–expressing CRPC cell lines (LNCaP95, VCaP-CR, and 22Rv1) and a patient-derived organoid model (LuCaP 167CR). We also explored the use of a Bcl-xL–specific proteolysis-targeting chimera degrader (PROTAC) to minimize platelet toxicity associated with Bcl-xL inhibitors. We showed similar synergistic efficacy with the Bcl-xL–targeting PROTAC in combination with S63845 in the three-dimensional spheroid models. Our findings support further preclinical development of Bcl-xL and Mcl-1 inhibitors for mCRPC.Significance:Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7–expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7–expressing CRPC.